Poor
Mostly Not Aligned
Patient Risk:
Medium
Summary
Only the portion of the response that addresses folic acid/folinic acid instructions by disease category (neoplastic vs non-neoplastic) is supported by the provided label text. Most other statements (e.g., multivitamins being usually not dangerous, safety of OTC multivitamins, general liver/kidney risk phrasing, and specific monitoring/likelihood assertions) are not supported or are broader than what the supplied label excerpts support.
Category Scores
Accurate Statements
Folate deficiency may increase TREXALL adverse reactions. Administer folic acid or folinic acid for patients with rheumatoid arthritis, pJIA, and psoriasis.
Supported by label section 5.10 (Non-neoplastic Diseases): 'Folate deficiency may increase TREXALL adverse reactions. Administer folic acid or folinic acid for patients with rheumatoid arthritis, pJIA, and psoriasis'.
Products containing folic acid or its derivatives may decrease the clinical effectiveness of methotrexate in neoplastic diseases, and patients should not take products containing folic acid or folinic acid unless directed by their healthcare provider.
Supported by label section 5.10 (Neoplastic Diseases): 'Products containing folic acid or its derivatives may decrease the clinical effectiveness of methotrexate... instruct patients not to take products containing folic acid or folinic acid unless directed...'
Methotrexate is contraindicated in pregnancy (for pregnant women receiving TREXALL for treatment of non-neoplastic diseases).
Supported by label section 4 (Contraindications): 'Pregnant women receiving TREXALL for treatment of non-neoplastic diseases'.
Advise patients to inform their healthcare provider of concomitant medications including vitamins and herbal products.
Supported by label section 17 (Patient Counseling Information): 'Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including... vitamins, and herbal products'.
Closely monitor patients with renal impairment for adverse reactions; reduce dosage or discontinue as appropriate.
Supported by label section 8.6: 'Patients with renal impairment are at increased risk... Closely monitor... Reduce the dosage or discontinue...'
Unsupported Statements
Folate support (often folic acid) is commonly used to reduce side effects in some patients taking methotrexate.
Provided label excerpt supports folic acid/folinic acid administration specifically for RA, pJIA, and psoriasis in the non-neoplastic context, but does not support a general statement about common use across 'some patients' or general side-effect reduction beyond that described instruction.
For most people on methotrexate, taking a typical over-the-counter multivitamin is not automatically dangerous.
No provided label excerpt supports that OTC multivitamins are generally safe/undangerous.
Risks of taking a multivitamin with methotrexate depend on what’s in the product and the methotrexate dose and schedule.
Label excerpt only instructs to avoid folic acid/folinic acid products unless directed in neoplastic diseases and to inform healthcare provider of concomitant vitamins/herbal products; it does not support a general dependency on dose/schedule for multivitamin risk.
Having folic acid in a multivitamin is usually not the problem in the context of methotrexate side-effect reduction.
Label supports folic acid/folinic acid administration for specific non-neoplastic indications to address folate deficiency adverse reactions; it does not support a blanket statement that folic-acid-containing multivitamins are 'usually not the problem' in side-effect reduction contexts.
The main risk concern with folic acid is safety and avoiding duplication if a clinician has prescribed folic acid on top of a multivitamin.
Provided label excerpt emphasizes decreased clinical effectiveness in neoplastic diseases and folate deficiency/adverse reactions in non-neoplastic diseases; it does not identify duplication/falsely increased safety as the 'main' risk concern.
Too much folic acid is not usually linked to the major toxicities.
No provided label excerpt supports this statement.
Doubling up folic acid can defeat the purpose of a planned regimen and can complicate monitoring.
Label excerpt does not support this general assertion about duplication defeating a regimen or complicating monitoring.
Alcohol and high-dose vitamins (especially when combined with other supplements) can matter for safety with methotrexate.
No provided label excerpt links alcohol or 'high-dose vitamins' generally to methotrexate safety; only general counseling to inform providers of concomitant vitamins/herbal products is supported.
Methotrexate can stress the liver.
Label excerpt does not support this phrasing as a standalone generalization; it only mentions hepatotoxicity as a category of toxicity in dosage modifications and patient counseling.
Heavy alcohol use or other factors that increase liver strain can worsen risk with methotrexate.
No provided label excerpt states alcohol or specific liver-strain factors modify risk.
Certain herbal products and supplements can affect liver enzymes or have additive toxicity concerns.
No provided label excerpt supports specific herbal effects such as liver enzyme changes or additive toxicity.
If a multivitamin includes herbs, it is more important to check.
The label supports informing healthcare providers about herbal products, but does not support the additional qualitative claim 'more important to check' for herb-containing multivitamins.
Potential risks include liver irritation or elevated liver tests with methotrexate.
Patient counseling excerpt says to report signs/symptoms of hepatic toxicity, but does not explicitly mention 'liver irritation' or 'elevated liver tests' in the provided text.
Potential risks include mouth sores. Potential risks include stomach irritation. Potential risks include blood count suppression.
While the label excerpt includes myelosuppression and need for monitoring and stomatitis reporting, it is not provided that 'mouth sores' and 'stomach irritation' are listed as such in the provided segments; additionally, these general phrasing statements are not supported as specific 'potential risks include' claims beyond the described counsel items.
Supplementation usually helps folate-related aspects, but the overall regimen still needs to be appropriate.
The label excerpt supports folic acid/folinic acid administration for specified non-neoplastic diseases, but does not support the general statement 'usually helps' or the broad regimen appropriateness framing.
There is a kidney-related accumulation risk if hydration is poor or kidney function is reduced. Multivitamins are usually not the direct cause of kidney-related accumulation risk.
Label excerpt supports increased risk in renal impairment and reduced elimination, but does not support hydration status causing accumulation risk or multivitamins 'not being the direct cause'.
Overlapping supplement use can add complexity to methotrexate management.
The label supports informing healthcare provider of vitamins/herbal products, but does not support this general 'complexity' claim.
It is especially important to ask a pharmacist or prescriber first if a person takes methotrexate weekly for rheumatoid arthritis or psoriasis and the doses are moderate to high.
Provided label excerpt does not include any dosing-threshold-based 'moderate to high' instruction for asking a pharmacist/prescriber.
It is especially important to ask a pharmacist or prescriber first if a person has kidney disease, liver disease, or heavy alcohol use.
Label excerpt supports informing providers of concomitant vitamins/herbal products and monitoring in renal/hepatic impairment, but does not include an explicit 'especially important' instruction tied to 'heavy alcohol use' or 'liver disease' in this context.
It is especially important to ask a pharmacist or prescriber first if a person already takes folic acid or folinic acid separately.
Label excerpt provides specific instructions about not taking folic acid/folinic acid products in neoplastic diseases unless directed, but does not support a general 'especially important' instruction for all scenarios including separate folic/folinic acid use in non-neoplastic indications.
It is especially important to ask a pharmacist or prescriber first if a multivitamin contains additional supplements such as herbs or high-dose vitamin A or other add-ons.
Label excerpt only broadly instructs to inform providers of all concomitant medications including vitamins and herbal products; it does not mention vitamin A specifically or provide add-on-specific counseling.
If a person is pregnant or trying to conceive, folate use must be handled through the care team.
Provided label excerpt supports pregnancy contraindication information for non-neoplastic disease and embryo-fetal toxicity counseling, but does not specifically address folate use when pregnant/trying to conceive.
Avoid 'stacking' supplements.
No provided label excerpt includes the instruction to avoid 'stacking' supplements.
If a prescriber told a patient to take folic acid, the patient should use that plan rather than adding multiple folate-containing products.
Label excerpt supports neoplastic disease instruction not to take folic acid/folinic acid products unless directed, but does not support a general recommendation about 'adding multiple folate-containing products' when a prescriber has already directed folic acid.
Keeping a single consistent product list and reviewing total doses with a pharmacist is recommended.
Label excerpt supports informing healthcare provider of concomitant medications including vitamins/herbal products, but does not specifically recommend 'reviewing total doses with a pharmacist' or 'single consistent product list'.
Contradictions
Important Omissions
Disease-category specificity when discussing folic acid/folinic acid: the label differentiates neoplastic vs non-neoplastic diseases (and provides specific counseling only for those contexts). The broader statements in the response sometimes fail to make that differentiation explicit.
Importance:
Moderate
Neoplastic-disease instruction is to avoid products containing folic acid or folinic acid unless directed by the healthcare provider; the response includes multiple general safety/dosing/duplication assertions that are not replaced by this specific counseling emphasis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several statements generalize folic acid/multivitamin safety and highlight duplication concerns without being supported by the provided label excerpts. In neoplastic diseases, the label instructs patients not to take folic acid/folinic acid products unless directed; insufficiently precise guidance could lead to omission of this key counseling in practice.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Overbroad, unsupported generalizations about multivitamin/folic acid safety, duplication, alcohol/herb effects, and risk likelihood that are not present in the supplied label excerpts.
Suggested Improvement
Restrict counseling to label-supported instructions: (1) for non-neoplastic RA/pJIA/psoriasis, administer folic acid or folinic acid for folate deficiency-related adverse reactions; (2) for neoplastic diseases, instruct patients not to take folic acid or folinic acid products unless directed; (3) advise patients to inform providers of all concomitant vitamins/herbal products; (4) in renal impairment, closely monitor and adjust dosage per label.